Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.17 USD
Change Today -0.17 / -1.50%
Volume 2.0M
NKTR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Stephen K. Doberstein Ph.D.

Chief Scientific Officer and Senior Vice President, Nektar Therapeutics
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 5 different industries.

55$2,139,127
As of Fiscal Year 2014

Background*

Dr. Stephen K. Doberstein, also known as Steve, Ph.D. has been Chief Scientific Officer and Senior Vice President of Nektar Therapeutics since January 6, 2010. Dr. Doberstein served as Vice President of Research of XOMA Ltd. since October 28, 2008. He has 17 years of experience in biotechnology research and development. Most recently, he served as Vice President of Research at Five Prime Therapeutics, Inc., since July 2004. Prior to his position at Five Prime, he served ...

Read Full Background

Corporate Headquarters*

455 Mission Bay Boulevard South
San Francisco, California 94158

United States

Phone: 415-482-5300
Fax: 415-339-5300

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

PhD
Johns Hopkins School of Medicine
BS
University of Delaware

Other Affiliations*

Annual Compensation*

Salary$477,583
Total Annual Compensation$477,583

Stock Options*

All Other Compensation$11,804
Exercisable Options724,580
Exercisable Options Value$4,426,624
Unexercisable Options175,420
Unexercisable Options Value$738,276
Total Value of Options$5,318,400
Total Number of Options1,000,000

Total Compensation*

Total Annual Cash Compensation$800,737
Total Short Term Compensation$477,583
Other Long Term Compensation$11,804
Total Calculated Compensation$2,139,127
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $11.17 USD -0.17

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President and Director
Theravance Inc.
$557.2K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
$620.1K
Peter S. Greenleaf Chief Executive Officer and Director
Sucampo Pharmaceuticals, Inc.
$440.2K
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director, Member of Strategic Operations Committee and Member of Pricing Committee
Emergent BioSolutions, Inc.
$1.2M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.